Integer Holdings Corp
NYSE:ITGR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (9.6), the stock would be worth $103.03 (19% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.1 | $86.81 |
0%
|
| 3-Year Average | 9.6 | $103.03 |
+19%
|
| 5-Year Average | 9.9 | $105.61 |
+22%
|
| Industry Average | 5.2 | $55.03 |
-37%
|
| Country Average | 6.5 | $69.58 |
-20%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| US |
I
|
Integer Holdings Corp
NYSE:ITGR
|
2.9B USD | 8.1 | 29 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 23.4 | 56.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 6.2 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 8.2 | 37.4 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 5.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 6.6 | 23.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 8.9 | 43.3 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 5.2 | 18.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 16.9 | 42.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 5.7 | 24 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 9.1 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.2 |
| Median | 6.5 |
| 70th Percentile | 10.6 |
| Max | 1 764 211.7 |
Other Multiples
Integer Holdings Corp
Glance View
Integer Holdings Corporation, a prominent player in the medical device industry, has carved a significant niche by aligning innovation with robust manufacturing capabilities. Founded as a collaborative effort between technical ingenuity and healthcare innovation, Integer primarily engages in the design and production of medical devices and components that are instrumental for the med-tech sector. It serves a diverse clientele that ranges from large healthcare conglomerates to emerging med-tech companies. The company operates through two main segments: Medical and Non-Medical. In the Medical division, Integer excels by providing critical components used in cardiac rhythm management, neuromodulation, and vascular access. It thrives on the premise that precision in manufacturing and innovation are key to producing reliable and effective medical solutions, ensuring that they meet stringent regulatory standards. What truly propels Integer’s financial engine is its commitment to operational excellence and strategic partnerships. By integrating vertically across its production processes, Integer achieves cost efficiencies that allow it to offer competitive pricing without sacrificing quality. Moreover, the company extends its influence through strategic partnerships with prominent healthcare providers, thereby securing long-term contracts and steady revenue streams. This model is supplemented by its Non-Medical segment, where Integer provides high-reliability components for energy, military, and environmental applications. These ventures not only diversify its revenue portfolio but also bolster its resilience against market volatility. Integer’s growth narrative is underscored by a relentless focus on research and development, which facilitates continuous product enhancement and keeps it at the forefront of technological advancement in the medical device industry. Through these strategies, Integer Holdings Corporation not only sustains its market position but also expands its role as a critical enabler in the global healthcare landscape.